Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290955 | 1.00 | HCAR2 (0.54) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL12125431 | 1.00 | HCAR2 (0.54) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL10125211 | 0.83 | HCAR2 (0.53) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL10592352 | 0.83 | HCAR2 (0.53) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL23130383 | 0.83 | HCAR2 (0.53) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL23306508 | 0.83 | CYP1A2 (0.47) | ALDH1A1NAAALMNA | |
| SCHEMBL10125207 | 0.83 | HCAR2 (0.53) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL15912310 | 0.83 | HCAR2 (0.53) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 | |
| SCHEMBL21798509 | 0.81 | FFAR2 (0.53) | ALDH1A1NAAAKMT2ASLC6A3 | |
| SCHEMBL21447183 | 0.81 | HCAR2 (0.51) | HCAR2LPAR1LPAR3OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273780-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | HCAR2 24/4885LPAR1 1/4885LPAR3 5/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | HCAR2 24/4885LPAR1 1/4885LPAR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.